title: Distinct roles for the A2B adenosine receptor in acute and chronic stages of bleomycin-induced lung injury.
abstract: Adenosine is an extracellular signaling molecule that is generated in response to cell injury where it orchestrates tissue protection and repair. Whereas adenosine is best known for promoting anti-inflammatory activities during acute injury responses, prolonged elevations can enhance destructive tissue remodeling processes associated with chronic disease states. The generation of adenosine and the subsequent activation of the adenosine 2B receptor (A(2B)R) is an important processes in the regulation of both acute and chronic lung disease. The goal of this study was to examine the contribution of the A(2B)R in models of bleomycin-induced lung injury that exhibit varying degrees of acute and chronic injury. Intratracheal bleomycin exposure results in substantial acute lung injury followed by progressive fibrosis. In this model, genetic removal of the A(2B)R resulted in enhanced loss of barrier function and increased pulmonary inflammation, with few differences in indexes of pulmonary fibrosis. These results support an anti-inflammatory role for this receptor in this model of acute lung injury. In contrast, systemic exposure of mice to bleomycin resulted in modest acute lung injury together with progressive pulmonary fibrosis. In this model, the effects of A(2B)R removal on acute lung injury were negligible; however, there were substantial reductions in pulmonary fibrosis, supporting a profibrotic role for this receptor. A(2B)R-dependent regulation of IL-6 production was identified as a potential mechanism involved in the diminished pulmonary fibrosis seen in A(2B)R knockout mice exposed to i.p. bleomycin. These studies highlight the distinct roles of A(2B)R signaling during acute and chronic stages of lung injury.
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Texas Medical School at Houston, Houston, TX 77030, USA.
authors.forename: Yang
authors.initials: Y
authors.lastname: Zhou
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Schneider
authors.forename: Eva
authors.initials: E
authors.lastname: Morschl
authors.forename: Ling
authors.initials: L
authors.lastname: Song
authors.forename: Mesias
authors.initials: M
authors.lastname: Pedroza
authors.forename: Harry
authors.initials: H
authors.lastname: Karmouty-Quintana
authors.forename: Thuy
authors.initials: T
authors.lastname: Le
authors.forename: Chun-Xiao
authors.initials: CX
authors.lastname: Sun
authors.forename: Michael R
authors.initials: MR
authors.lastname: Blackburn
mesh_terms: D000208:Acute Disease; D055371:Acute Lung Injury / Q000139:chemically induced* / Q000378:metabolism* / Q000473:pathology; D000818:Animals; D001761:Bleomycin / Q000633:toxicity*; D002908:Chronic Disease; D018836:Inflammation Mediators / Q000378:metabolism / Q000502:physiology; D007442:Intubation, Intratracheal; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D043704:Receptor, Adenosine A2B / Q000172:deficiency / Q000235:genetics / Q000502:physiology*
chemical_list: D018836:Inflammation Mediators; D043704:Receptor, Adenosine A2B; D001761:Bleomycin